New Alzheimer’s Drug Pending Full FDA Approval

June 26, 2023 On June 1, 2023, the Centers for Medicare & Medicaid Services (CMS) announced the possibility of Medicare coverage for a new Alzheimer’s drug.   The Food and Drug Administration (FDA) is currently evaluating a new drug shown to slow the progression of Alzheimer’s disease. Pending full approval, CMS reports that Medicare is…

June 26, 2023

On June 1, 2023, the Centers for Medicare & Medicaid Services (CMS) announced the possibility of Medicare coverage for a new Alzheimer’s drug.  

The Food and Drug Administration (FDA) is currently evaluating a new drug shown to slow the progression of Alzheimer’s disease. Pending full approval, CMS reports that Medicare is prepared to cover the drug, lecanemab (Leqembi), in select settings.

The FDA approved Leqembi under an accelerated approval pathway earlier this year, however Medicare does not yet offer coverage for the drug. In early July, the FDA will make a final decision on full approval. If the FDA grants traditional approval, the new drug will be covered for anyone with Medicare Part B who meets the necessary criteria.

Does Medicare cover Alzheimer’s care?

Original Medicare does not offer comprehensive coverage for Alzheimer’s care but may cover some care costs. Medicare may cover inpatient care and some medically necessary supplies related to Alzheimer’s disease.

What is Medicare Part B?

Under Part B, Medicare will cover medically necessary services and supplies. Learn more about Medicare Part B.